hcc: considerations in first-line use of sorafenib
Published 7 years ago • 1.2K plays • Length 6:02Download video MP4
Download video MP3
Similar videos
-
8:50
first-line therapy in advanced hcc
-
8:10
dosing strategies with sorafenib in hcc
-
5:40
sorafenib initiation after tace in hcc
-
1:02
dr. kudo discusses tace plus sorafenib in hcc
-
1:27
dr. pinato on study of sorafenib in pretreated patients with hcc
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
2:28
nrg/rtog 1112: sorafenib vs sbrt followed by sorafenib in hcc
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
4:30
regorafenib following first-line systemic therapy in hcc
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
5:26
hcc whiteboard #1: the epidemiology of hepatocellular carcinoma and current standard of care
-
4:35
hcc treatment: sorafenib tace
-
4:16
frontline therapy for hcc: optimizing treatment selection
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
4:06
managing toxicities with sorafenib in hcc
-
2:01
qol analyses from rationale-301 of tislelizumab vs sorafenib in hcc
-
7:01
global use of regorafenib in hcc
-
7:29
understanding how best to sequence in advanced hcc
-
3:12
tislelizumab os benefit vs sorafenib as first line treatment for unresectable hepatocellular car...